UNSPSC 51312501: Arpromidine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25FN6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85713MT0EH, chemically known as guanidine, n-(3-(4-fluorophenyl)-3-(2-pyridinyl)propyl)-n-(3-(1h-imidazol-4-yl)propyl)- but generally known as arpromidine, which bears US NIH Compound Identifier 65895. European Medicines Agency schedules Arpromidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05570MIG.

UNSPSC 51312501 Arpromidine is a Commodity code, but the recent state and local solicitation activity under this code does not align with pharmaceutical arpromidine procurement. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking to procure naloxone and safe drug deactivation systems—a public health and emergency response product line that falls outside the nominal scope of this code. The county's need is concrete: 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and all shipping and delivery costs included in vendor pricing. The contract terms include an initial two-year period with a one-year renewal option, a three-month probationary period, and potential FEMA funding with associated federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act.

The recent opportunity record shows little activity relevant to the arpromidine code itself. Seminole County is the sole recent issuing body named, and the procurement is geographically concentrated in central Florida. Vendors responding to the Seminole County solicitation must meet electronic bid submission requirements through the county's e-Procurement Portal, provide unit costs for each line item, and maintain workers' compensation, commercial general liability, and professional liability insurance. Bidders must achieve drug-free workplace certification and E-Verify compliance, with no explicit set-asides named for disadvantaged enterprises. The IFB had a response deadline of July 26, 2023 (a past date relative to the June 30, 2026 posting date, suggesting a data inconsistency in the source), and the county will award on a fixed-fee basis. This code shows minimal traceable recent activity and warrants close monitoring for future state and local naloxone and harm-reduction procurement rather than pharmaceutical arpromidine supply.